Founded in Lexington, MA, Hemanext is a medical technology company dedicated to advancing transfusion medicine. With a mission to save lives and improve patient outcomes, Hemanext focuses on innovative blood processing and storage solutions. Their flagship product, Hemanext ONE, is an FDA-authorized technology designed to mitigate the red blood cell (RBC) storage lesion, enhancing the quality and efficacy of stored blood. The company operates a research and development center in Lexington and a manufacturing facility in Avon, MA, serving a global market.
Hemanext has garnered attention from notable figures in the biomedical field and secured investments from leading healthcare investors. The company’s pioneering work in hypoxically stored RBCs has led to significant advancements in transfusion medicine, positioning it as a key player in the industry. Through its innovative solutions, Hemanext has made a substantial impact on improving the therapeutic value of blood transfusions, ultimately contributing to better patient care and outcomes worldwide.
